Impact of N-Glycan Analysis on Drug Efficacy

Glycosylation Modification (N-Glycan)

Glycosylation is one of the most common post-translational modifications in eukaryotic proteins. It occurs on the surface of the endoplasmic reticulum (ER), where glycosyltransferases catalyze the attachment of glycans to asparagine residues in newly synthesized proteins via N-glycosidic bonds. These modified residues are located at the Asn-X-Thr/Ser (X≠Pro) motif and undergo further processing in the ER and Golgi apparatus.

All eukaryotic N-glycans share a common core sequence: Manα1-3 [Manα1-6] Manβ1-4GlcNAcβ1-4GlcNAcβ1-N-Asn-X-Ser/Thr. There are three main types of N-glycans:

1.High-Mannose Type: Only mannose residues extend from the core.

2.Complex Type: GlcNAc initiates core extension.

3.Hybrid Type: Man initiates the extension of the Manα1-6 arm, while GlcNAc initiates the Manα1-3 arm.

Impact of Glycosylation on Drug Properties

The N-glycan type at the N297 site of monoclonal antibodies (mAbs) is closely related to Fc effector functions:

• Reducing or removing fucose and N-acetylglucosamine increases the binding of the Fc region to FcγRⅢa (CD16a), enhancing ADCC effects.
• Increasing terminal galactose levels enhances CDC effects by improving C1q binding.
• High-mannose N-glycans can bind mannose receptors, leading to mAb degradation and a reduced half-life.
• Non-human monosaccharides (α-galactose, N-glycolylneuraminic acid) may trigger immunogenicity.
• Antibodies with highly sialylated Fc glycans exhibit anti-inflammatory effects.

Complex proteins with highly sialylated N-glycans maintain stability. However, desialylation exposes galactose, N-acetylglucosamine, or mannose, promoting degradation and reducing protein half-life.

Commercial antibodies contain multiple glycan types, and variations in glycan types and ratios between batches can cause efficacy fluctuations. Producing antibodies with consistent glycan profiles ensures stable product properties across batches.

N-Glycan Detection

Regulatory Requirements

N-glycosylation significantly affects the biological function, half-life, immunogenicity, solubility, thermal stability, protease resistance, and aggregation of proteins. It is a key indicator of batch-to-batch consistency in antibody production.

ICH-Q6B, various pharmacopoeias, and regulatory authorities have established quantitative requirements for N-glycan analysis. The 2025 edition of the Chinese Pharmacopoeia details the measurement and analysis methods under "9405 Glycoprotein Glycosylation Analysis Guidelines" and "3130 N-Glycan Profiling Method."

N-Glycan Detection Methods and Workflow

The N-glycan detection workflow includes:

• Rapid enzymatic cleavage with PNGase F.
• Labeling with derivatization reagents.
• Purification.

• LC-MS analysis.

Hzymes offers a complete range of solutions:

• Rapid Fluorescence Labeling Kits, 2-AB Labeling Kits, and ProA Labeling Kits to cover all glycan analysis methods.

• Total operation time is under one hour, with no time-consuming steps like lyophilization.

• High fluorescence signal ensures accurate and consistent results.

Glycosylation Modification (N-Glycan)

Impact of Glycosylation on Drug Properties

N-Glycan Detection

Regulatory Requirements

N-Glycan Detection Methods and Workflow

Hzymes offers a complete range of solutions:

Product Performance

Complete PNGase F Digestion: 5-minute rapid digestion with CE-SDS verification.

Consistent Glycan Data: Peak retention time and ratios match imported brands.

Linear Validation: Correlation coefficient (R²) > 0.99.

Batch Consistency: Produced under strict GMP standards.

Durability: Consistent peak ratios over time.

Customer Evaluation: Consistent data with rapid labeling and 2-AB labeling kits.

Product Information